News Roche poised to buy MASH drug developer 89bio for $3.5bn Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.
News Rumour mill has Camurus buying partner Braeburn Camurus is said to be in talks to acquire US partner Braeburn in a deal that would give it control of their product for treating opioid use disorder.
News Zentiva set to change hands in €4.1bn private equity deal Ex-Sanofi generics company Zentiva is poised for a sale by current owner Advent International to US investment group GTCR, says a media report.
News Novartis nabs cardio drug with $1.4bn Tourmaline buy Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).
News Remedy Meds buys telehealth rival in $500m marriage Telehealth startup Remedy Meds has expanded its position in the US market at a stroke with a $500m-plus deal to buy Thirty Madison.
News IPO plan evaporates as private equity firm buys Stada Stada has confirmed it isn't going ahead with an IPO, as its two private equity owners have just agreed to sell a majority stake to a third.
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.